Phase II clinical trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, RA Wolff, JL Abbruzzese… - Journal of Clinical …, 2006 - ascopubs.org
14151 Background: Pancreatic cancer is virtually always lethal, and the only FDA-approved
therapies-gemcitabine and erlotinib-produce objective responses in less than 10% of …
therapies-gemcitabine and erlotinib-produce objective responses in less than 10% of …
Phase II clinical trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, RA Wolff, JL Abbruzzese, DS Hong… - Journal of Clinical …, 2006 - cir.nii.ac.jp
抄録< jats: p> 14151</jats: p>< jats: p> Background: Pancreatic cancer is virtually always
lethal, and the only FDA-approved therapies-gemcitabine and erlotinib-produce objective …
lethal, and the only FDA-approved therapies-gemcitabine and erlotinib-produce objective …